In this fourth annual Respiratory e-book, learn more about Porex and Nemera and their contributions to inhalation drug delivery and device design.
PLATFORM DEVICE – Alina: Shining the “Light” on the Benefits of a Platform Approach to Treating Chronic Conditions
Adam Stops, PhD, says the key to the success of any drug delivery device are factors such as proven technology, low development costs, fast time-to-market, and a strong intellectual property (IP) position for the pharma company, and against this background, platform drug delivery devices have become more important than ever.
Contributor Cindy H. Dubin speaks with several leading CDMOs from around the globe on their unique development and manufacturing capabilities and technologies, and presents real-world examples of how they have put these to use to produce innovative compounds, lower development costs, and shorten time to market.
FORMULATION FORUM – PLGA – A Versatile Copolymer for Design & Development of Nanoparticles for Drug Delivery
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the chemistry, properties, applications, and regulatory aspects of PLGA, and the future trends in the industry, especially those requiring the development of long-acting injectables for the treatment of a variety of rare diseases and for life cycle management.
DRUG DEVELOPMENT – Overcoming Challenges on the Path From Candidate Selection to First-in-Human Clinical Testing
Eleanor Row, PhD, explores the current challenges drug developers face in transitioning their candidate molecules to first-in-human (FIH) clinical trials, including what the different drug development functions should be considering at this stage, and how an integrated approach can help to accelerate your molecule’s pathway to trial and beyond.
Chris Preti, President of Jubilant HollisterStier, discusses how the CMO is handling increased demand for sterile fill finish and how expertise makes a difference to customer relationships and finished product quality.
Ross Errington explores the latest developments in the pMDI segment and explains the steps pharmaceutical companies need to take to ensure their pMDI drug products are ready to thrive in a very different market environment.
Darren Hieber discusses his company’s progress after his first year as Sr. Vice President of Corporate Development and Partnerships at Lifecore Biomedical.
EXCIPIENT TECHNOLOGY – A Juggling Act: Factors at Play in Your Choice of Solubilizing Parenteral Excipients
Joey Glassco, MBA, says the power of novel excipients such as Apisolex polymer could revolutionize the parenteral drug development landscape, effectively solubilizing a wide range of APIs without compromising on safety or stability.
Amy Brown says one of the most effective ways to gather valuable, relevant, and useful information from a clinical trial is by listening to conversations at scale, helping researchers understand the psychosocial factors influencing and affecting a specific patient population.
EXCLUSIVE ONLINE CONTENT
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
EXECUTIVE INTERVIEW – Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.